Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Alan Williams, Rina Mbofung, Daniel Morales-Mantilla, Brian Groff, Alison O'Connor, Binzhong Li, Ramesh Janani, Betsy Rezner, Mark Jelcic, Yijia Pan, Tom Lee, Karl-Johan Malmberg, Maksim Mamonkin, John Goulding, Jode Goodridge, Bahram Valamehr

Blood (2024) 144 (Supplement 1): 503.

https://doi.org/10.1182/blood-2024-210846

Published: 2024

Journal Articles

Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells

Bryan Hancock, Jonatan Tuncel, Kyla Omilusik, Alison O'Connor, Bi-Huei Yang, Matthew Haynes, Amanda Yzaguirre, Karina Palomares, Sandeep Kothapally Hanok, Matthew Denholtz, Martin Hosking, Eigen Peralta, Tom Lee, Raedun Clarke, Sjoukje Van Der Stegen, John Goulding, Jode Goodridge, Michel Sadelain, Bahram Valamehr

Blood (2024) 144 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2024-210786

Published: 2024

Journal Articles

Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

Blood (2024) 144 (Supplement 1): 4801.

https://doi.org/10.1182/blood-2024-209465

Published: 2024

Journal Articles

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

Blood (2022) 140 (23): 2451–2462.

https://doi.org/10.1182/blood.2021015184

Published: 2022

Includes: Supplemental data

Journal Articles

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesus G. Berdeja, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour

Blood (2022) 140 (Supplement 1): 4586–4587.

https://doi.org/10.1182/blood-2022-166994

Published: 2022

Journal Articles

The Development of Allogeneic Tips-Derived TCR - CAR + CD8αβ T Cells

Sjoukje J.C. van der Stegen, Roseanna M. Petrovic, Pieter L. Lindenbergh, Mame P. Diop, Vera Alexeeva, Hongyao Xie, Raedun Clarke, Bahram Valamehr, Isabelle Rivière, Michel Sadelain

Blood (2022) 140 (Supplement 1): 10290–10291.

https://doi.org/10.1182/blood-2022-169375

Published: 2022

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

Multi-Antigen Targeting By Novel Combination of CAR-T Cells and hnCD16 Transgene, Yields in Complete Tumor Clearance Via Antibody Dependent Cellular Cytotoxicity

Soheila Shirinbak, Joy Grant, Wen-I Yeh, Angela Gentile, Bishwas Shrestha, Bi-Huei Yang, Mochtar Pribadi, Shohreh Sikaroodi, Amit Mehta, Amanda D Yzaguirre, Yijia Pan, Chia-Wei Chang, Tom Lee, Layton Smith, Jianming Wu, Bruce Walcheck, Martin Hosking, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 10253–10254.

https://doi.org/10.1182/blood-2022-169462

Published: 2022

Journal Articles

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

Rina M Mbofung, Xingyue Zong, Erika Varady, Alan M Williams, Ken L Hayama, Yijia Pan, Sushil Devkota, Brian Groff, Miguel Meza, Thomas Dailey, Tom Lee, Lilly Wong, Sarah Cooley, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 7388–7389.

https://doi.org/10.1182/blood-2022-169817

Published: 2022

Journal Articles

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Quirin Hammer, Karlo Perica, Rina M Mbofung, Hanna van Ooijen, Erika Varady, Mark Jelcic, Yijia Pan, Pouria Momayyezi, Brian Groff, Ramzey Abujarour, Silje Zandstra Krokeide, Tom Lee, Alan M Williams, Jode P Goodridge, Bahram Valamehr, Bjorn Onfelt, Michel Sadelain, Karl-Johan Malmberg

Blood (2022) 140 (Supplement 1): 1165–1166.

https://doi.org/10.1182/blood-2022-163086

Published: 2022

Journal Articles

Characterization of Engineered Macrophages and Other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells

Samuel Labarge, Amanda Sims, Joseph Sandoval, Anil Bagri, Alec Witty, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 2859–2860.

https://doi.org/10.1182/blood-2022-170231

Published: 2022

Journal Articles

High-Density Cryopreservation of Off-the-Shelf CAR-NK Cells Facilitates On-demand Treatment Access

Ya-Ju Chang, Niancao Chen, Christine Chen, Tingxia Guo, Jaslem Herrera Valdez, Svetlana Gaidarova, Bryan Hancock, Betsy Rezner, Yvonne Lentz, Mark Plavsic, Richard Anderson, Raedun Clarke, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4693–4694.

https://doi.org/10.1182/blood-2022-162712

Published: 2022

Journal Articles

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

Alan M Williams, Ken L Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Amber Chang, Christine Chen, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Maksim Mamonkin, Raedun Clarke, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4547–4548.

https://doi.org/10.1182/blood-2022-167139

Published: 2022

Journal Articles

FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

John Reiser, Szeman Ruby Chan, Ketan Mathavan, David Sillitti, Cristina Mottershead, Bethany Mattson, Melissandre Pache, Alma Gutierrez, Whitney Scoon, Yanni Zhu, Andrew Gilder, Christine Chen, Kimberly Staquet, Michael Ports, Charles Drake, Joseph Erhardt, Ryan Bjordahl, Jode P. Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4560–4561.

https://doi.org/10.1182/blood-2022-170501

Published: 2022

Journal Articles

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, Ravi Vij

Blood (2022) 140 (Supplement 1): 10327–10328.

https://doi.org/10.1182/blood-2022-166728

Published: 2022

Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park

Blood (2022) 140 (Supplement 1): 4577–4578.

https://doi.org/10.1182/blood-2022-167194

Published: 2022

Journal Articles

CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium with the Hematopoietic Lineage Potency to Give Rise to Bona Fide Lymphocytes

Amanda D Yzaguirre, Carissa Dege, Daniel Sivalingam, Rahel Schnellmann, Alec Witty, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 5728–5729.

https://doi.org/10.1182/blood-2022-169989

Published: 2022

Journal Articles

A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape

Eigen Peralta, Dan Lu, Mark Landon, Hui-yi Chu, Soo Park, Masanao Tsuda, Trevor Zarecki, Elena Demeester, Matthew Denholtz, Amit Mehta, Earl Avramis, Philip Chu, Jeffrey Chen, Eric Sung, Alec Witty, Tom Lee, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 7429–7430.

https://doi.org/10.1182/blood-2022-169887

Published: 2022

Journal Articles

Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape

Bi-Huei Yang, Yu-Sheng Eason Lin, Soheila Shirinbak, Wen-I Yeh, Mochtar Pribadi, Hui-Yi Chu, Alma Gutierrez, Amit Mehta, Earl Avramis, Roseanna Petrovic, Benjamin Whitlock, Jason ORourke, Sjoukje van der Stegen, Tom Lee, Alec Witty, Eigen Peralta, Martin Hosking, Chia-Wei Chang, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 2793.

https://doi.org/10.1182/blood-2021-153268

Published: 2021

Journal Articles

Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection

Rina M Mbofung, Alan M Williams, Ken Hayama, Yijia Pan, Brian Groff, Thomas Dailey, Sonia Reyes, Sajid Mahmood, Ketan Mathavan, Greg Bonello, Quirin Hammer, Karl-Johan Malmberg, Tom Lee, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 2795.

https://doi.org/10.1182/blood-2021-153484

Published: 2021

NARROW

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells

Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

The Development of Allogeneic Tips-Derived TCR - CAR + CD8αβ T Cells

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Multi-Antigen Targeting By Novel Combination of CAR-T Cells and hnCD16 Transgene, Yields in Complete Tumor Clearance Via Antibody Dependent Cellular Cytotoxicity

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Characterization of Engineered Macrophages and Other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells

High-Density Cryopreservation of Off-the-Shelf CAR-NK Cells Facilitates On-demand Treatment Access

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium with the Hematopoietic Lineage Potency to Give Rise to Bona Fide Lymphocytes

A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape

Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape

Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only